|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical trial:Lactobacillus plantarum 299v(DSM 9843)improves symptoms of irritable bowel syndrome显示文摘AIM:To assess the symptomatic efficacy of Lactobacillus plantarum 299v(L.plantarum 299v)(DSM 9843) for the relief of abdominal symptoms in a large subset of irritable bowel syndrome(IBS) patients fulfilling the Rome Ⅲ criteria.METHODS:In this double blind,placebo-controlled,parallel-designed study,subjects were randomized to daily receive either one capsule of L.plantarum 299v(DSM 9843) or placebo for 4 wk.Frequency and intensity of abdominal pain,bloating and feeling of incomplete rectal emptying were assessed weekly on a visual analogue scale while stool frequency was calculated.RESULTS:Two hundred and fourteen IBS patients were recruited.After 4 wk,both pain severity(0.68 + 0.53 vs 0.92 + 0.57,P < 0.05) and daily frequency(1.01 + 0.77 vs 1.71 + 0.93,P < 0.05) were lower with L.plantarum 299v(DSM 9843) than with placebo.Similar results were obtained for bloating.At week 4,78.1 % of the patients scored the L.plantarum 299v(DSM 9843) symptomatic effect as excellent or good vs only 8.1 % for placebo(P < 0.01).CONCLUSION:A 4-wk treatment with L.plantarum 299v(DSM 9843) provided effective symptom relief,particularly of abdominal pain and bloating,in IBS patients fulfilling the Rome Ⅲ criteria. | Philippe Ducrotté Prabha Sawant Venkataraman Jayanthi | 2012 | World Journal of Gastroenterology2012，18，30： | 17 |
| 2 | Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome:A randomized,double-blind study显示文摘AIM:To assess the effects and safety of Lactobacillus casei rhamnosus LCR35 complete freeze-dried culture(LCR35) in patients suffering from irritable bowel syndrome(IBS).METHODS:A randomized,double-blind pilot study was performed in 50 patients complaining of IBS symptoms complying with RomeⅢcriteria.Patients were allocated to receive either LCR35(n = 25) at a minimum daily dose of 6 × 108 colony forming units or placebo(n = 25) for 4 wk.At inclusion,after treatment and 2 wk later,patients completed the IBS severity scale.Change from baseline in the IBS severity score at the end of treatment was the primary efficacy criterion.Changes were compared between groups in the whole population and in IBS subtypes(IBS with predominance of constipation,IBS with predominance of diarrhoea,mixed IBS,unsubtyped IBS).The presence of lactobacillus casei rhamnosus in stools was investigated at inclusion and at the end of treatment.The gastrointestinal quality of life questionnaire and the hospital anxiety and depression(HAD) scale were also completed.RESULTS:Both groups were balanced for baseline characteristics.In 85% of patients,stool analyses showed that lactobacillus casei rhamnosus able to survive in the digestive tract.In the whole population,improvements in the IBS severity score did not differ significantly between treatments with a 25% decrease after 4-wk treatment,and a 15% decrease from baseline 2 wk later in both groups.In IBS subgroups,statistical analysis could not be performed due to small sample size,but a clinical response in favour of LCR35 was observed in IBS patients with predominance of diarrhoea:no change in the symptom severity score was seen with the placebo after 4 wk treatment,whereas a clinically relevant decrease occurred with LCR35(-37% vs-3%).Furthermore,in spite of an increase in symptom intensity,the IBS severity score was maintained below the baseline value 2 wk later with LCR35(-19% from baseline),whilst a slight 5% increase from baseline was observed with placebo.In the IBS subgroup with predominance of diarrhoea only,a clinically relevant decrease in abdominal pain severity score(-36%)was observed with LCR35,whereas no change occurred with placebo.In mixed IBS patients,the 20% and 30% decreases in the IBS severity score observed after treatment with LCR35 and placebo,respectively,were maintained 2 wk later in both groups.A clinical response slightly in favour of placebo was observed at the end of the treatment period in IBS patients with predominance of constipation(-41% vs-20%) and unsubtyped IBS patients(-47% vs-17%),with the same value maintained 2 wk later.In both groups,no clinically relevant changes were observed either for the gastrointestinal quality of life index or HAD score.Thus,these results suggest that sub-grouping of IBS patients may be important for optimizing treatment responses by the physician.CONCLUSION:This pilot study suggests that LCR35 could have some efficacy in IBS patients complaining of diarrhoea.These preliminary results need to be conf irmed in larger studies. | Michel Dapoigny Thierry Piche Philippe Ducrotte Bernard Lunaud Jean-Michel Cardot Annick Bernalier-Donadille | 2012 | World Journal of Gastroenterology2012，18，17： | 10 |
| 3 | Effects of glutamine supplementation on gut barrier,glutathione content and acute phase response in malnourished rats during inflammatory shock显示文摘AIM: To evaluate the effect of glutamine on intestinal mucosa integrity,glutathione stores and acute phase response in protein-depleted rats during an inflammatory shock. METHODS: Plasma acute phase proteins (APP),jejunal APP mRNA levels,liver and jejunal glutathione concentrations were measured before and one,three and seven days after turpentine injection in 4 groups of control,protein-restricted,protein-restricted rats supplemented with glutamine or protein powder. Bacterial translocation in mesenteric lymph nodes and intestinal morphology were also assessed. RESULTS: Protein deprivation and turpentine injection significantly reduced jejunal villus height,and crypt depths. Mucosal glutathione concentration significantly decreased in protein-restricted rats. Before turpentine oil,glutamine supplementation restored villus heights and glutathione concentration (3.24 ± 1.05 vs 1.72 ± 0.46 μmol/g tissue,P < 0.05) in the jejunum,whereas in the liver glutathione remained low. Glutamine markedly increased jejunal α1-acid glycoprotein mRNA level after turpentine oil but did not affect its plasma concentration. Bacterial translocation in protein-restricted rats was not prevented by glutamine or protein powder supplementation. CONCLUSION: Glutamine restored gut glutathione stores and villus heights in malnourished rats but had no preventive effect on bacterial translocation in our model. | Liliana Belmonte Mose Co■ffier Florence Le Pessot Olga Miralles-Barrachina Martine Hiron Antony Leplingard Jean-Franois Lemeland Bernadette Hecketsweiler Maryvonne Daveau Philippe Ducrotté Pierre Déchelotte | 2007 | World Journal of Gastroenterology2007，13，20： | 6 |
| 4 | Factors Associated With Diagnosis of Obscure Gastrointestinal Bleeding by Video Capsule Enteroscopy显示文摘 | Lucie Lepileur Xavier Dray Michel Antonietti Isabelle Iwanicki–Caron Sébastien Grigioni Ulriikka Chaput Aude Di–Fiore Raied Alhameedi Philippe Marteau Philippe Ducrotté Stéphane Lecleire | 2012 | Clinical Gastroenterology and Hepatology2012，，12： | 2 |
| 5 | Duodenal intraepithelial T lymphocytes in patients with functional dyspepsia显示文摘AIM: To quantify the intraepithelial lymphocytes (IELs) and to document the membrane expression of CD4, CD8, TCRγδ and adhesion and/or activation-associated molecules (CD103, CD28, CD44, CD69, HLA-DR, CD95/ Fas) in the duodenal mucosa of patients with functional dyspepsia (FD) in order to provide arguments for an immunological process in FD. METHODS: Twenty-six FD patients according to Rome Ⅱ criteria (20 were H pylori negative) were studied and compared to 12 healthy adults. IELs were isolated from five duodenal biopsy samples, then quantified by microscopy and flow cytometry while the membrane phenotypes were determined by cytofluorometry. RESULTS: Duodenal histological examination was normal. In H pylori negative patients, the number of IELs was not different from that in healthy controls. Median percentage expression of CD4, CD8, or TCRγδ and CD103, CD44, CD28, CD69 on CD3+ IELs, among the adhesion/activation associated molecules tested, was not different from that in healthy controls. In contrast, the median percentage expression of CD95/ Fas [22 (9-65) vs 45 (19-88), P = 0.03] and HLA- DR expressing CD3+ IELs [4 (0-30) vs 13 (4-42), P = 0.04] was significantly lower in the H pylori negative FD group than in healthy controls, respectively. The number of IELs was significantly greater in H pylori positive FD patients than in healthy controls [median ratiofor 100 enterocytes 27.5 (6.7-62.5) vs 10.8 (3-33.3), P = 0.02] due to a higher number of CD8+ CD3+ IELs. CONCLUSION: In H pylori negative FD patients, the phenotypic characterization of IELs suggests that we cannot exclude a role of IELs in FD. | Gilles Gargala Stéphane Lecleire Arnaud Franois Serge Jacquot Pierre Déchelotte Jean Jacques Ballet Loic Favennec Philippe Ducrotté | 2007 | World Journal of Gastroenterology2007，13，16： | 2 |
| 6 | Motility of the Roux-en-Y hepaticojejunostomy in asymptomatic patients显示文摘 | Isabelle Le Blanc-Louvry Philippe Ducrotté Jean Luc Manouvrier Christophe Peillon Jacques Testart Philippe Denis | 1999 | The American Journal of Gastroenterology1999，，9： | 2 |
| 7 | Tenatoprazole,a novel proton pump inhibitor with a pro- longed plasma half-life: effects on intragastric pH andcomparison with esomeprazole in healthy volunteers 显示文摘 | Galmiche J P Bruley Des Varannes S Ducrotte P | 2004 | Aliment Pharma Ther2004，19，6： | 1 |
| 8 | Biofeedback training for constipation in adults and children显示文摘 | Weber J Ducrotte P Touchais JY | 1987 | Dis Colon Rectum1987，30，11： | 1 |
| 9 | Motility of the Roux-en-Y hepaticojejunostomy in asymptomatic patients 显示文摘 | Le Blanc-Louvry I Ducrotte P Manouvrier JL | 1999 | Am J Gastroenterol1999，94，9： | 1 |
| 10 | Tenatoprazole,a novel proton pump inhibitor with a prolonged plasma half-life:effects on intragastric pH and comparison with esomeprazole in healthy volunteers显示文摘 | Galmiche JP Bruley Des Varannes S Ducrotté P | | 0，，： | 1 |
| 11 | Effect of a fer mented milk containing Bifidobacteriurn animalis DN-173010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, ran- domized, double-blind, controlled trial显示文摘 | Guyonnet D Chassany O Ducrotte P | 2007 | Aliment Pharmacol Ther2007，26，3： | 1 |
| 12 | Newgeneration proton pump inhibitors:progress in the treatnent of peptic acid diseases显示文摘 | Korwin JD Ducrotte P Vallot T | 2004 | Presse Med2004，33，11： | 1 |
| 13 | Modulating effect of glutamine on IL-1 beta-induced cytokine produetion by human gut显示文摘 | Coeffifer M Marion R Ducrotte P | 2003 | Clin Nutr2003，22，： | 1 |
| 14 | Effect of a fer -mented milk containing bifidobacterium animalis DN - 173 010 on the health - related quality of life and symptomsin irri2table bowel syndrome in adults in primary care: a multicentre, randomized, double - blind, controlled trial 显示文摘 | Guyonnet D Chassany O Ducrotte P | 2007 | Aliment Pharmacol Ther2007，26，： | 1 |
| 15 | Roux-en-Y limbmotility after total or distal gastrectomy in symptomatic and asymptomatic patients显示文摘 | Le Blanc LL Ducrotte P Peillon C | 2000 | J Am Coll Surg2000，190，4： | 1 |
| 16 | Prevalence of functional gastrointestinal disorders in a population of suects consulting for gastroesophageal refluxsease in general practice 显示文摘 | Guillemot F Ducrotte P Bueno L | 2005 | Gastroenterol Clin Biol2005，29，3： | 1 |
| 17 | Effect of a fermented milk containing Bifidobacterium animalis DN-173010 on the health- related quality of life and symptoms in irritable bowel syndrome in adults in primary care : a muhicentre, randomized, double-blind, controlled trial显示文摘 | Guyonnet D Chassany O Ducrotte P | 2007 | Aliment Pharmacol Ther2007，26，3： | 1 |
| 18 | Simultaneous recordings of oesophageal acid exposure with conventional pH monitoring and a wireless system (Bravo) 显示文摘 | Des Varannes SB Mion F Ducrotte P | 2005 | Gut2005，54，12： | 1 |
| 19 | Tenatoprazole,a novel proton pump inhibitor with a prolonged plasma half-life:effects on intragastric pH and comparison with esomeprazole in healthy volunteers显示文摘 | Galmiche JP Ducrotte P Sacher HS | 2004 | Aliment Pharmacol Ther2004，19，6： | 1 |
| 20 | Endoscopic markers of villous atrophy are not useful for the detection of celiac disease in patients with dyspeptic symptoms显示文摘 | S. Lecleire F. Di Fiore M. Antonietti G. Savoye F. Lemoine F. Le Pessot E. Lerebours P. Ducrotté | 2006 | Endoscopy2006，，07： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员